Investigational drugs for recurrent or primary advanced metastatic cervical cancer: what is in the clinical development pipeline?

References

• Cohen PA, Jhingran A, Oaknin A, et al. Cervical cancer. Lancet. 2019 Jan 12;393(10167):169–182.
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–249.
   PubMed Web of Science ®Google Scholar
• Wild CP, Weiderpass E, Stewart BW. World cancer report: cancer research for cancer prevention. Lyon France: International Agency for Research on Cancer; 2020. Available from: https://publications.iarc.fr/586.
   Google Scholar
• de Martel C, Plummer M, Vignat J, et al. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141(4):664–670.
   PubMed Web of Science ®Google Scholar
• Poddar P, Maheshwari A. Surgery for cervical cancer: consensus & controversies. Indian J Med Res. 2021 Aug;154(2):284–292.
   PubMedGoogle Scholar
• Cohen AC, Roane BM, Leath CA 3rd. Novel therapeutics for recurrent cervical cancer: moving towards personalized therapy. Drugs. 2020;80(3):217–227.
   PubMed Web of Science ®Google Scholar
• Schmidt A-M, Imesch P, Fink D, et al. Indications and long-term clinical outcomes in 282 patients with pelvic exenteration for advanced or recurrent cervical cancer. Gynecol Oncol. 2012 Jun;125(3):604–609.
   PubMed Web of Science ®Google Scholar
• Li H, Wu X, Cheng X. Advances in diagnosis and treatment of metastatic cervical cancer. J Gynecol Oncol. 2016 Jul;27(4):e43.
   PubMed Web of Science ®Google Scholar
• Kitagawa R, Katsumata N, Shibata T, et al. Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III trial JCOG0505. J Clin Oncol. 2015 Jul 1;33(19):2129–2135.
   PubMed Web of Science ®Google Scholar
• Koh WJ, Abu-Rustum NR, Bean S, et al. Cervical cancer, version 3.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019 Jan;17(1):64–84.
   PubMed Web of Science ®Google Scholar
• Colombo N, Dubot C, Lorusso D, et al. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. N Engl J Med. 2021 Nov 11;385(20):1856–1867.
   PubMed Web of Science ®Google Scholar
• FDA. FDA approves pembrolizumab combination for the first-line treatment of cervical cancer: U.S Food and Drug Administration; 2021 [23 Jan 31]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-combination-first-line-treatment-cervical-cancer
   Google Scholar
• Tewari KS, Colombo N, Monk BJ, et al. Pembrolizumab + chemotherapy in patients with persistent, recurrent, or metastatic cervical cancer: subgroup analysis of KEYNOTE-826. J Clin Oncol. 2022;40(16_suppl):5506.
   Google Scholar
• Pang SS, Murphy M, Markham MJ. Current management of locally advanced and metastatic cervical cancer in the United States. JCO Oncol Pract. 2022;18(6):417–422.
   PubMedGoogle Scholar
• Gennigens C, Jerusalem G, Lapaille L, et al. Recurrent or primary metastatic cervical cancer: current and future treatments. ESMO Open. 2022 Oct;7(5):100579.
   PubMed Web of Science ®Google Scholar
• Saito T, Takehara M, Tanaka R, et al. Correlation between responsiveness of neoadjuvant chemotherapy and apoptosis-associated proteins for cervical adenocarcinoma. Gynecol Oncol. 2004 Jan;92(1):284–292.
   PubMedGoogle Scholar
• Musa FB, Brouwer E, Ting J, et al. Trends in treatment patterns and costs of care among patients with advanced stage cervical cancer. Gynecol Oncol. 2022 Mar;164(3):645–650.
   PubMedGoogle Scholar
• McLachlan J, Boussios S, Okines A, et al. The impact of systemic therapy beyond first-line treatment for advanced cervical cancer. Clin Oncol (R Coll Radiol). 2017 Mar;29(3):153–160.
   PubMedGoogle Scholar
• FDA. FDA grants accelerated approval to tisotumab vedotin-tftv for recurrent or metastatic cervical cancer: food and Drug Administration; 2021 [23 Jan 31]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-tisotumab-vedotin-tftv-recurrent-or-metastatic-cervical-cancer
   Google Scholar
• Committee for Medicinal Products for Human Use. LIBTAYO® (CEMIPLIMAB) receives positive opinion from CHMP for marketing authorisation European Medicines Agency; 2022 [23 Jan 31]. Available from: https://www.ema.europa.eu/en/medicines/human/summaries-opinion/libtayo-0
   Google Scholar
• Tucker N. Cemiplimab FDA approval application for recurrent or metastatic cervical cancer withdrawn targeted oncology 2022 [2023 Jan 31]. Available from: https://www.targetedonc.com/view/cemiplimab-fda-approval-application-for-recurrent-or-metastatic-cervical-cancer-withdrawn
   Google Scholar
• Burmeister CA, Khan SF, Schäfer G, et al. Cervical cancer therapies: current challenges and future perspectives. Tumour Virus Res. 2022 Jun;13:200238.
   PubMedGoogle Scholar
• Tewari KS, Sill MW, Penson RT, et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet. 2017 Oct 7;390(10103):1654–1663.
   PubMed Web of Science ®Google Scholar
• Stafl A, Mattingly RF. Angiogenesis of cervical neoplasia. Am J Obstet Gynecol. 1975 Mar 15;121(6):845–852.
   PubMed Web of Science ®Google Scholar
• Vergote I, Van Nieuwenhuysen E, Casado A, et al. Randomised double-blind Phase II BGOG/ENGOT-cx1 study of paclitaxel-carboplatin with nintedanib/placebo in first-line recurrent or primary advanced cervical cancer. European Congress on Gynecological Oncology; Prague, Czech Republic 2021.
   Google Scholar
• Symonds RP, Gourley C, Davidson S, et al. Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncol. 2015 Nov;16(15):1515–1524.
   PubMed Web of Science ®Google Scholar
• Wang J, Sun H, Zeng Q, et al. HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma. Sci Rep. 2019 Sep 16;9(1):13404.
   PubMed Web of Science ®Google Scholar
• Duranti S, Pietragalla A, Daniele G, et al. Role of immune checkpoint inhibitors in cervical cancer: from preclinical to clinical data. Cancers (Basel). 2021 Apr 26;13(9):2089.
   PubMedGoogle Scholar
• Zahn LM. Effects of the tumor microenvironment. Science. 2017 Mar 31;355(6332):1386–1388.
   Google Scholar
• Morad G, Helmink BA, Sharma P, et al. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 2021 Oct 14;184(21):5309–5337.
   PubMed Web of Science ®Google Scholar
• Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 2020 Jul 30;11(1):3801.
   PubMed Web of Science ®Google Scholar
• Heeren AM, Punt S, Bleeker MC, et al. Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix. Mod Pathol. 2016 Jul;29(7):753–763.
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723.
   PubMed Web of Science ®Google Scholar
• Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, et al. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7875–7880.
   PubMed Web of Science ®Google Scholar
• Yano H, Andrews LP, Workman CJ, et al. Intratumoral regulatory T cells: markers, subsets and their impact on anti-tumor immunity. Immunology. 2019 Jul;157(3):232–247.
   PubMed Web of Science ®Google Scholar
• Huang YH, Zhu C, Kondo Y, et al. CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature. 2015 Jan 15;517(7534):386–390.
   PubMed Web of Science ®Google Scholar
• Stanietsky N, Simic H, Arapovic J, et al. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Acad Sci U S A. 2009 Oct 20;106(42):17858–17863.
   PubMed Web of Science ®Google Scholar
• Yu X, Harden K, Gonzalez LC, et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol. 2009 Jan;10(1):48–57.
   PubMed Web of Science ®Google Scholar
• Frumovitz M, Westin SN, Salvo G, et al. Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract. Gynecol Oncol. 2020 Sep;158(3):570–575.
   PubMedGoogle Scholar
• Chung HC, Ros W, Delord JP, et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2019 Jun 10;37(17):1470–1478.
   PubMed Web of Science ®Google Scholar
• Santin AD, Deng W, Frumovitz M, et al. Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002). Gynecol Oncol. 2020 Apr;157(1):161–166.
   PubMed Web of Science ®Google Scholar
• Naumann RW, Hollebecque A, Meyer T, et al. Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I/II CheckMate 358 trial. J Clin Oncol. 2019 Nov 1;37(31):2825–2834.
   PubMed Web of Science ®Google Scholar
• Loverix L, Salihi R, van Rompuy A-S, et al. 2022-RA-1263-ESGO Phase II randomized BGOG-CX3 trial comparing atezolizumab in combination with doxorubicin versus doxorubicin alone in second-line or later recurrent cervical cancer. Int J Gynecol Cancer. 2022;32(Suppl 2):A51–A51.
   Google Scholar
• Oaknin A, Monk BJ, Vergote I, et al. EMPOWER CERVICAL-1: effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer. Eur J Cancer. 2022 Oct;174:299–309.
   PubMedGoogle Scholar
• Tewari KS, Monk BJ, Vergote I, et al. Survival with cemiplimab in recurrent cervical cancer. N Engl J Med. 2022 Feb 10;386(6):544–555.
   PubMed Web of Science ®Google Scholar
• Lan C, Shen J, Wang Y, et al. Camrelizumab plus apatinib in patients with advanced cervical cancer (CLAP): a multicenter, open-label, single-arm, phase II trial. J Clin Oncol. 2020 Dec 1;38(34):4095–4106.
   PubMed Web of Science ®Google Scholar
• Zhang X, Chen J, Liu N, et al. Camrelizumab (SHR-1210) with carboplatin and albumin-binding paclitaxel in patients with metastatic or recurrent cervical cancer: an open-label, phase 2 trial. J Cancer Res Ther. 2022 Apr;18(2):482–487.
   PubMedGoogle Scholar
• O’Malley DM, Calo CA. Progress in gynecologic cancers with antibody drug conjugates. Curr Oncol Rep. 2021 Jun 14;23(8):89.
   PubMedGoogle Scholar
• O’Malley DM, Neffa M, Monk BJ, et al. Dual PD-1 and CTLA-4 checkpoint blockade using balstilimab and zalifrelimab combination as second-line treatment for advanced cervical cancer: an open-label phase II study. J Clin Oncol. 2022 Mar 1;40(7):762–771.
   PubMed Web of Science ®Google Scholar
• Rosa K. Agenus withdraws BLA for balstilimab in metastatic cervical cancer: onclive; 2021 [23 Jan 31]. Available from: https://www.onclive.com/view/agenus-withdraws-bla-for-balstilimab-in-metastatic-cervical-cancer
   Google Scholar
• Ge Z, Peppelenbosch MP, Sprengers D, et al. TIGIT, the next step towards successful combination immune checkpoint therapy in cancer. Front Immunol. 2021;12:699895.
   PubMedGoogle Scholar
• Liu L, Wang A, Liu X, et al. Blocking TIGIT/CD155 signalling reverses CD8(+) T cell exhaustion and enhances the antitumor activity in cervical cancer. J Transl Med. 2022 Jun 21;20(1):280.
   PubMedGoogle Scholar
• Tamura K, Hasegawa K, Katsumata N, et al. Efficacy and safety of nivolumab in Japanese patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma: multicenter, open-label phase 2 trial. Cancer Sci. 2019 Sep;110(9):2894–2904.
   PubMed Web of Science ®Google Scholar
• O’Malley DM, Oaknin A, Monk BJ, et al. Phase II study of the safety and efficacy of the anti-PD-1 antibody balstilimab in patients with recurrent and/or metastatic cervical cancer. Gynecol Oncol. 2021 Nov;163(2):274–280.
   PubMed Web of Science ®Google Scholar
• Youn JW, Hur SY, Woo JW, et al. Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial. Lancet Oncol. 2020 Dec;21(12):1653–1660.
   PubMed Web of Science ®Google Scholar
• Lheureux S, Butler MO, Clarke B, et al. Association of ipilimumab with safety and antitumor activity in women with metastatic or recurrent human papillomavirus-related cervical carcinoma. JAMA Oncol. 2018 Jul 12;4(7):e173776.
   PubMed Web of Science ®Google Scholar
• Friedman CF, Snyder Charen A, Zhou Q, et al. Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer. J Immunother Cancer. 2020;8:2.
   Web of Science ®Google Scholar
• Huh WK, Brady WE, Fracasso PM, et al. Phase II study of axalimogene filolisbac (ADXS-HPV) for platinum-refractory cervical carcinoma: an NRG oncology/gynecologic oncology group study. Gynecol Oncol. 2020 Sep;158(3):562–569.
   PubMedGoogle Scholar
• Melief CJM, Welters MJP, Vergote I, et al. Strong vaccine responses during chemotherapy are associated with prolonged cancer survival. Sci Transl Med. 2020 Mar 18;12(535):535.
   Google Scholar
• Rischin D, Gil-Martin M, González-Martin A, et al. PD-1 blockade in recurrent or metastatic cervical cancer: data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer. Gynecol Oncol. 2020 Nov;159(2):322–328.
   PubMed Web of Science ®Google Scholar
• Mayadev JS, Enserro D, Lin YG, et al. Sequential ipilimumab after chemoradiotherapy in curative-intent treatment of patients with node-positive cervical cancer. JAMA Oncol. 2020 Jan 1;6(1):92–99.
   PubMedGoogle Scholar
• Xu Q, Wang J, Sun Y, et al. Efficacy and safety of sintilimab plus anlotinib for PD-L1-positive recurrent or metastatic cervical cancer: a multicenter, single-arm, prospective phase II trial. J Clin Oncol. 2022 Jun 1;40(16):1795–1805.
   PubMed Web of Science ®Google Scholar
• Jung KH, LoRusso P, Burris H, et al. Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors. Clin Cancer Res. 2019 Jun 1;25(11):3220–3228.
   PubMed Web of Science ®Google Scholar
• Coleman RL, Lorusso D, Gennigens C, et al. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021 May;22(5):609–619.
   PubMed Web of Science ®Google Scholar
• de Bono JS, Concin N, Hong DS, et al. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial. Lancet Oncol. 2019 Mar;20(3):383–393.
   PubMed Web of Science ®Google Scholar
• Hong DS, Concin N, Vergote I, et al. Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer. Clin Cancer Res. 2020 Mar 15;26(6):1220–1228.
   PubMedGoogle Scholar
• Vergote IB, Monk BJ, O’Cearbhaill RE, et al. 723MO Tisotumab vedotin (TV) + carboplatin (Carbo) in first-line (1L) or + pembrolizumab (Pembro) in previously treated (2L/3L) recurrent or metastatic cervical cancer (r/mCC): interim results of ENGOT-Cx8/GOG-3024/innovaTV 205 study. Ann Oncol. 2021 Oct 01;32:S726–S727.
   PubMedGoogle Scholar
• Lorusso D, Vergote I, O’Cearbhaill RE, et al. Tisotumab vedotin (TV) + pembrolizumab (pembro) in first-line (1L) recurrent or metastatic cervical cancer (r/mCC): interim results of ENGOT Cx8/GOG 3024/innovaTV 205. J Clin Oncol. 2022;40(16_suppl):5507.
   Google Scholar
• Yonemori K, Kuboki Y, Hasegawa K, et al. Tisotumab vedotin in Japanese patients with recurrent/metastatic cervical cancer: results from the innovaTV 206 study. Cancer Sci. 2022 Aug 01;113(8):2788–2797.
   PubMedGoogle Scholar
• Zhang L, Chen L, Phase YH. II study of apatinib, a novel tyrosine kinase inhibitor targeting tumor angiogenesis, as second-line treatment for recurrent or advanced cervical cancer patients. Invest New Drugs. 2020 Aug;38(4):1186–1191.
   PubMedGoogle Scholar
• Guo Q, Sun Y, Kong E, et al. Apatinib combined with chemotherapy or concurrent chemo-brachytherapy in patients with recurrent or advanced cervical cancer: a phase 2, randomized controlled, prospective study. Medicine (Baltimore). 2020 Mar;99(11):e19372.
   PubMedGoogle Scholar
• Pignata S, Scambia G, Lorusso D, et al. The MITO CERV-2 trial: a randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer. Gynecol Oncol. 2019 Jun;153(3):535–540.
   PubMedGoogle Scholar
• Redondo A, Colombo N, McCormack M, et al. Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer. Gynecol Oncol. 2020 Oct;159(1):142–149.
   PubMedGoogle Scholar
• Suzuki K, Nagao S, Shibutani T, et al. Phase II trial of paclitaxel, carboplatin, and bevacizumab for advanced or recurrent cervical cancer. Gynecol Oncol. 2019 Sep;154(3):554–557.
   PubMedGoogle Scholar
• Ishikawa M, Shibata T, Iwata T, et al. A randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab versus dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311): primary analysis. Gynecol Oncol. 2021 Aug;162(2):292–298.
   PubMedGoogle Scholar
• Tanigawa T, Takeshima N, Ishikawa H, et al. Paclitaxel-carboplatin and bevacizumab combination with maintenance bevacizumab therapy for metastatic, recurrent, and persistent uterine cervical cancer: an open-label multicenter phase II trial (JGOG1079). Gynecol Oncol. 2022 Jun;165(3):413–419.
   PubMedGoogle Scholar
• Vergote IB, Lund B, Peen U, et al. Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies. Gynecol Oncol. 2020 Feb;156(2):308–314.
   PubMed Web of Science ®Google Scholar
• Mabuchi S, Yokoi E, Shimura K, et al. A phase II study of irinotecan combined with S-1 in patients with advanced or recurrent cervical cancer previously treated with platinum based chemotherapy. Int J Gynecol Cancer. 2019 Mar;29(3):474–479.
   PubMedGoogle Scholar
• Oaknin A, Friedman CF, Roman LD, et al. Neratinib in patients with HER2-mutant, metastatic cervical cancer: findings from the phase 2 SUMMIT basket trial. Gynecol Oncol. 2020 Oct;159(1):150–156.
   PubMed Web of Science ®Google Scholar
• Liu JF, Gray KP, Wright AA, et al. Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer. Gynecol Oncol. 2019;154(1):95–101.
   PubMed Web of Science ®Google Scholar
• Shapiro-Frommer R, Perets R, Voskoboynik M, et al. Safety and efficacy of vibostolimab plus pembrolizumab in patients with cervical cancer naive to PD-1/PD-L1 inhibitors in KEYVIBE-001. American Association for Cancer Research; New Orleans, Louisiana 2022.
   Google Scholar
• Zhu Y, Zhou J, Zhu L, et al. Adoptive tumor infiltrating lymphocytes cell therapy for cervical cancer. Hum Vaccin Immunother. 2022 Nov 30;18(5):2060019.
   PubMedGoogle Scholar
• Stevanović S, Draper LM, Langhan MM, et al. Complete Regression of metastatic cervical cancer after treatment with human papillomavirus–targeted tumor-infiltrating T cells. J Clin Oncol. 2015 May 10;33(14):1543–1550.
   PubMed Web of Science ®Google Scholar
• Sousa LGD, Rajapakshe K, Rodriguez Canales J, et al. ISA101 and nivolumab for HPV-16 + cancer: updated clinical efficacy and immune correlates of response. J Immunother Cancer. 2022;10(2):e004232.
   PubMed Web of Science ®Google Scholar
• Förster Y, Meye A, Albrecht S, et al. Tissue factor and tumor: clinical and laboratory aspects. Clin Chim Acta. 2006 Feb;364(1–2):12–21.
   PubMed Web of Science ®Google Scholar
• Vergote I, Mirza M, Sehouli R, et al. Trial in progress update on ENGOT-cx8/GOG-3024/innovaTV 205: addition of a new cohort with first-line (1L) tisotumab vedotin (TV) + pembrolizumab (pembro) + carboplatin (carbo) ± bevacizumab (bev) in recurrent/metastatic cervical cancer (r/mCC) J Clin Oncol. 2022;40(16_suppl):5603.
   Google Scholar
• Kim SK, Ursell P, Coleman RL, et al. Mitigation and management strategies for ocular events associated with tisotumab vedotin. Gynecol Oncol. 2022 May;165(2):385–392.
   PubMedGoogle Scholar
• Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387(1):9–20.
   PubMed Web of Science ®Google Scholar
• Schilder RJ, Sill MW, Lee Y-C, et al. A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. Int J Gynecol Cancer. 2009;19(5):929–933–929–933.
   Google Scholar
• Goncalves A, Fabbro M, Lhommé C, et al. A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer. Gynecol Oncol. 2008;108(1):42–46.
   PubMedGoogle Scholar
• Monk BJ, Mas Lopez L, Zarba JJ, et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. J Clin Oncol. 2010 Aug 1;28(22):3562–3569.
   PubMed Web of Science ®Google Scholar
• Ling Y, Liu J, Qian J, et al. Recent advances in multi-target drugs targeting protein kinases and histone deacetylases in cancer therapy. Curr Med Chem. 2020;27(42):7264–7288.
   PubMedGoogle Scholar
• Coquan E, Brachet P-E, Licaj I, et al. CABOCOL-01 trial: a single-arm phase II study assessing safety and efficacy of Cabozantinib for advanced or metastatic cervical carcinoma after platinum treatment failure. BMC Cancer. 2021 Aug 25;21(1):1054.
   PubMedGoogle Scholar
• Coquan E, Lequesne J, Colomba E, et al. 2022-RA-579-ESGO A phase II study assessing safety and efficacy of cabozantinib for advanced or metastatic cervical carcinoma after platinum treatment failure (CABOCOL study). Int J Gynecol Cancer. 2022;32(Suppl 2):A14–A14.
   Google Scholar